Skip to main content
Erschienen in: Journal of General Internal Medicine 7/2020

27.04.2020 | Original Research

Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals

verfasst von: Albert Do, M.D., M.P.H, Denise A. Esserman, Ph.D., Supriya Krishnan, Sc.D., Joseph K. Lim, M.D., Tamar H. Taddei, M.D., Ronald G. Hauser III, M.D., Janet P. Tate, M.P.H., Sc.D., Vincent Lo Re III, M.D., Amy C. Justice, M.D., Ph.D.

Erschienen in: Journal of General Internal Medicine | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Cure from chronic hepatitis C virus (HCV) infection is readily achievable with direct-acting antivirals (DAA), but little is known about optimal management after treatment. Weight gained after DAA treatment may mitigate benefits or increase risk for liver disease progression. As the single largest sample of HCV-infected individuals receiving DAA treatment in the United States, the Veterans Affairs (VA) Birth Cohort is an ideal setting to assess weight gain after DAA treatment.

Methods

We performed a prospective study of patients dispensed DAA therapy from January 2014 to June 2015. Weight change was calculated as the difference in weight from sustained virologic response (SVR) determination to 2 years later. Demographic, weight, height, prescription, laboratory, and diagnosis code data were used for covariate definitions. We used multiple logistic regression to assess the association between candidate predictors and excess weight gain (≥ 10 lbs) after 2 years.

Results

Among 11,469 patients, 78.0% of patients were already overweight or obese at treatment initiation. Overall, SVR was achieved in 97.0% of patients. After 2 years, 52.6% of patients gained weight and 19.8% gained excess weight. In those with SVR, weight gain was as high as 38.2 lbs, with the top 10% gaining ≥ 16.5 lbs. Only 1% of those with obesity at treatment initiation normalized their weight class after 2 years. Significant predictors of post-SVR weight gain were SVR achievement, lower age, high FIB-4 score, cirrhosis, and weight class at treatment initiation.

Conclusion

Weight gain is common after DAA treatment, even among those who are overweight or obese prior to treatment. Major predictors include age, baseline weight, alcohol, cirrhosis, and SVR. Everyone receiving DAAs should be counseled against weight gain with a particular emphasis among those at higher risk.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 2016;36 Suppl 1:47–57.PubMedCrossRef Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 2016;36 Suppl 1:47–57.PubMedCrossRef
2.
Zurück zum Zitat Ampuero J, Romero-Gomez M. Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3. Gastroenterol Clin North Am 2015;44:845–857.PubMedCrossRef Ampuero J, Romero-Gomez M. Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3. Gastroenterol Clin North Am 2015;44:845–857.PubMedCrossRef
3.
Zurück zum Zitat Alqahtani S, Sulkowski M. Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. Gastroenterol Clin North Am 2015;44:825–843.PubMedCrossRef Alqahtani S, Sulkowski M. Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. Gastroenterol Clin North Am 2015;44:825–843.PubMedCrossRef
4.
Zurück zum Zitat Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology 2017;152:1578–1587.PubMedCrossRef Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. Gastroenterology 2017;152:1578–1587.PubMedCrossRef
5.
Zurück zum Zitat El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 2016;64:130–137.PubMedCrossRef El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 2016;64:130–137.PubMedCrossRef
6.
Zurück zum Zitat Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease. Hepatology 2017. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease. Hepatology 2017.
7.
Zurück zum Zitat Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-Acting Antiviral Sustained Virologic Response: Impact on Mortality in Patients without Advanced Liver Disease. Hepatology 2018. Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-Acting Antiviral Sustained Virologic Response: Impact on Mortality in Patients without Advanced Liver Disease. Hepatology 2018.
8.
Zurück zum Zitat Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut 2018:gutjnl-2018-316234. Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut 2018:gutjnl-2018-316234.
9.
Zurück zum Zitat Conjeevaram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, Hoofnagle JH, Virahep CSG. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology 2011;140:469–477.PubMedCrossRef Conjeevaram HS, Wahed AS, Afdhal N, Howell CD, Everhart JE, Hoofnagle JH, Virahep CSG. Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology 2011;140:469–477.PubMedCrossRef
10.
Zurück zum Zitat Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444–2451.PubMedCrossRef Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444–2451.PubMedCrossRef
11.
Zurück zum Zitat Fioravante M, Alegre SM, Marin DM, Lorena SL, Pereira TS, Soares EC. Weight loss and resting energy expenditure in patients with chronic hepatitis C before and during standard treatment. Nutrition 2012;28:630–634.PubMedCrossRef Fioravante M, Alegre SM, Marin DM, Lorena SL, Pereira TS, Soares EC. Weight loss and resting energy expenditure in patients with chronic hepatitis C before and during standard treatment. Nutrition 2012;28:630–634.PubMedCrossRef
12.
Zurück zum Zitat Sugimoto R, Iwasa M, Hara N, Tamai Y, Yoshikawa K, Ogura S, Tanaka H, et al. Changes in liver function and body composition by direct-acting antiviral therapy for hepatitis C virus infection. Hepatol Res 2017. Sugimoto R, Iwasa M, Hara N, Tamai Y, Yoshikawa K, Ogura S, Tanaka H, et al. Changes in liver function and body composition by direct-acting antiviral therapy for hepatitis C virus infection. Hepatol Res 2017.
13.
Zurück zum Zitat Schlevogt B, Deterding K, Port K, Siederdissen CHZ, Sollik L, Kirschner J, Mix C, et al. Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up. Z Gastroenterol 2017;55:848–856.PubMedCrossRef Schlevogt B, Deterding K, Port K, Siederdissen CHZ, Sollik L, Kirschner J, Mix C, et al. Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up. Z Gastroenterol 2017;55:848–856.PubMedCrossRef
14.
Zurück zum Zitat Malnick SD, Knobler H. The medical complications of obesity. Journal of the Association of Physicians 2006;99:565–579. Malnick SD, Knobler H. The medical complications of obesity. Journal of the Association of Physicians 2006;99:565–579.
15.
Zurück zum Zitat Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in Obesity Among Adults in the United States, 2005 to 2014. JAMA 2016;315:2284–2291.PubMedCrossRef Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in Obesity Among Adults in the United States, 2005 to 2014. JAMA 2016;315:2284–2291.PubMedCrossRef
16.
Zurück zum Zitat Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766–781.PubMedPubMedCentralCrossRef Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766–781.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84.PubMedCrossRef Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84.PubMedCrossRef
18.
Zurück zum Zitat Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547–555.PubMedCrossRef Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, Ahmed A. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547–555.PubMedCrossRef
19.
Zurück zum Zitat Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9:524–530 e521; quiz e560.PubMedCrossRef Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9:524–530 e521; quiz e560.PubMedCrossRef
20.
Zurück zum Zitat El-serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460–468.PubMedCrossRef El-serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460–468.PubMedCrossRef
21.
Zurück zum Zitat Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, Hunt S. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62:1723–1730.PubMedCrossRef Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, Hunt S. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62:1723–1730.PubMedCrossRef
22.
Zurück zum Zitat Ascha MS, Hanouneh IA, Lopez R, Tamimi TAR, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972–1978.PubMedCrossRef Ascha MS, Hanouneh IA, Lopez R, Tamimi TAR, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972–1978.PubMedCrossRef
23.
Zurück zum Zitat Sarkar S, Esserman DA, Skanderson M, Levin FL, Justice AC, Lim JK. Disparities in hepatitis C testing in U.S. veterans born 1945-1965. J Hepatol 2016;65:259–265.PubMedPubMedCentralCrossRef Sarkar S, Esserman DA, Skanderson M, Levin FL, Justice AC, Lim JK. Disparities in hepatitis C testing in U.S. veterans born 1945-1965. J Hepatol 2016;65:259–265.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012;157:817–822.PubMedPubMedCentralCrossRef Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med 2012;157:817–822.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Backus LI, Belperio PS, Loomis TP, Yip GH, Mole LA. Hepatitis C virus screening and prevalence among US veterans in Department of Veterans Affairs care. JAMA Intern Med 2013;173:1549–1552.PubMedCrossRef Backus LI, Belperio PS, Loomis TP, Yip GH, Mole LA. Hepatitis C virus screening and prevalence among US veterans in Department of Veterans Affairs care. JAMA Intern Med 2013;173:1549–1552.PubMedCrossRef
26.
Zurück zum Zitat Dutton GR, Kim Y, Jacobs Jr DR, Li X, Loria CM, Reis JP, Carnethon M, et al. 25-year weight gain in a racially balanced sample of US adults: The CARDIA study. Obesity 2016;24:1962–1968.PubMedCrossRef Dutton GR, Kim Y, Jacobs Jr DR, Li X, Loria CM, Reis JP, Carnethon M, et al. 25-year weight gain in a racially balanced sample of US adults: The CARDIA study. Obesity 2016;24:1962–1968.PubMedCrossRef
27.
Zurück zum Zitat Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis 1972;25:329–343.PubMedCrossRef Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. J Chronic Dis 1972;25:329–343.PubMedCrossRef
28.
Zurück zum Zitat Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski MS, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317–1325.PubMedCrossRef Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski MS, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317–1325.PubMedCrossRef
29.
Zurück zum Zitat Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013;158:825–830.PubMedCrossRef Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013;158:825–830.PubMedCrossRef
30.
Zurück zum Zitat Lee KJ, Carlin JB. Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation. American journal of epidemiology 2010;171:624–632.PubMedCrossRef Lee KJ, Carlin JB. Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation. American journal of epidemiology 2010;171:624–632.PubMedCrossRef
31.
Zurück zum Zitat Nishitsuji H, Funami K, Shimizu Y, Ujino S, Sugiyama K, Seya T, Takaku H, et al. Hepatitis C virus infection induces inflammatory cytokines and chemokines mediated by the cross talk between hepatocytes and stellate cells. J Virol 2013;87:8169–8178.PubMedPubMedCentralCrossRef Nishitsuji H, Funami K, Shimizu Y, Ujino S, Sugiyama K, Seya T, Takaku H, et al. Hepatitis C virus infection induces inflammatory cytokines and chemokines mediated by the cross talk between hepatocytes and stellate cells. J Virol 2013;87:8169–8178.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, Romano C, et al. Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013;5:528–540.PubMedPubMedCentralCrossRef Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, Romano C, et al. Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013;5:528–540.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Foster G, Goldin R, Thomas H. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209–212.PubMedCrossRef Foster G, Goldin R, Thomas H. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209–212.PubMedCrossRef
34.
Zurück zum Zitat Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis 2016;3:3–14.PubMedPubMedCentral Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis 2016;3:3–14.PubMedPubMedCentral
35.
Zurück zum Zitat Periyalwar P, Dasarathy S. Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clinics in liver disease 2012;16:95–131.PubMedPubMedCentralCrossRef Periyalwar P, Dasarathy S. Malnutrition in cirrhosis: contribution and consequences of sarcopenia on metabolic and clinical responses. Clinics in liver disease 2012;16:95–131.PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Hanai T, Shiraki M, Nishimura K, Ohnishi S, Imai K, Suetsugu A, Takai K, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition 2015;31:193–199.PubMedCrossRef Hanai T, Shiraki M, Nishimura K, Ohnishi S, Imai K, Suetsugu A, Takai K, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition 2015;31:193–199.PubMedCrossRef
38.
Zurück zum Zitat Gowda C, Brown TT, Compher C, Forde KA, Kostman J, Shaw PA, Tien PC. Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection. AIDS (London, England) 2016;30:2519.CrossRef Gowda C, Brown TT, Compher C, Forde KA, Kostman J, Shaw PA, Tien PC. Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection. AIDS (London, England) 2016;30:2519.CrossRef
39.
Zurück zum Zitat Gowda C, Compher C, Amorosa VK, Lo Re III V. Association between chronic hepatitis C virus infection and low muscle mass in US adults. Journal of viral hepatitis 2014;21:938–943.PubMedPubMedCentralCrossRef Gowda C, Compher C, Amorosa VK, Lo Re III V. Association between chronic hepatitis C virus infection and low muscle mass in US adults. Journal of viral hepatitis 2014;21:938–943.PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat St-Onge MP, Gallagher D. Body composition changes with aging: the cause or the result of alterations in metabolic rate and macronutrient oxidation? Nutrition 2010;26:152–155.PubMedCrossRef St-Onge MP, Gallagher D. Body composition changes with aging: the cause or the result of alterations in metabolic rate and macronutrient oxidation? Nutrition 2010;26:152–155.PubMedCrossRef
41.
Zurück zum Zitat Herrin M, Tate JP, Akgun KM, Butt AA, Crothers K, Freiberg MS, Gibert CL, et al. Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals. J Acquir Immune Defic Syndr 2016;73:228–236.PubMedPubMedCentralCrossRef Herrin M, Tate JP, Akgun KM, Butt AA, Crothers K, Freiberg MS, Gibert CL, et al. Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals. J Acquir Immune Defic Syndr 2016;73:228–236.PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes care 2011:DC_102415. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes care 2011:DC_102415.
43.
Zurück zum Zitat Blackburn G. Effect of degree of weight loss on health benefits. Obesity research 1995;3:211s–216s. Blackburn G. Effect of degree of weight loss on health benefits. Obesity research 1995;3:211s–216s.
44.
Zurück zum Zitat Goldstein DJ. Beneficial health effects of modest weight loss. International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity 1992;16:397–415. Goldstein DJ. Beneficial health effects of modest weight loss. International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity 1992;16:397–415.
45.
Zurück zum Zitat Caton S, Ball M, Ahern A, Hetherington M. Dose-dependent effects of alcohol on appetite and food intake. Physiology & behavior 2004;81:51–58.CrossRef Caton S, Ball M, Ahern A, Hetherington M. Dose-dependent effects of alcohol on appetite and food intake. Physiology & behavior 2004;81:51–58.CrossRef
46.
Zurück zum Zitat Lieber CS. Relationships between nutrition, alcohol use, and liver disease. Alcohol Research and Health 2003;27:220–231.PubMedPubMedCentral Lieber CS. Relationships between nutrition, alcohol use, and liver disease. Alcohol Research and Health 2003;27:220–231.PubMedPubMedCentral
47.
Zurück zum Zitat Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterology & hepatology 2011;7:661. Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterology & hepatology 2011;7:661.
48.
Zurück zum Zitat Kim DD, Basu A. Estimating the medical care costs of obesity in the United States: systematic review, meta-analysis, and empirical analysis. Value in Health 2016;19:602–613.PubMedCrossRef Kim DD, Basu A. Estimating the medical care costs of obesity in the United States: systematic review, meta-analysis, and empirical analysis. Value in Health 2016;19:602–613.PubMedCrossRef
49.
Zurück zum Zitat Breland JY, Phibbs CS, Hoggatt KJ, Washington DL, Lee J, Haskell S, Uchendu US, et al. The Obesity Epidemic in the Veterans Health Administration: Prevalence Among Key Populations of Women and Men Veterans. J Gen Intern Med 2017;32:11–17.PubMedPubMedCentralCrossRef Breland JY, Phibbs CS, Hoggatt KJ, Washington DL, Lee J, Haskell S, Uchendu US, et al. The Obesity Epidemic in the Veterans Health Administration: Prevalence Among Key Populations of Women and Men Veterans. J Gen Intern Med 2017;32:11–17.PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Williams PT, Wood PD. The effects of changing exercise levels on weight and age-related weight gain. International journal of obesity 2006;30:543.PubMedCrossRef Williams PT, Wood PD. The effects of changing exercise levels on weight and age-related weight gain. International journal of obesity 2006;30:543.PubMedCrossRef
51.
Zurück zum Zitat Lovasi GS, Hutson MA, Guerra M, Neckerman KM. Built environments and obesity in disadvantaged populations. Epidemiologic reviews 2009;31:7–20.PubMedCrossRef Lovasi GS, Hutson MA, Guerra M, Neckerman KM. Built environments and obesity in disadvantaged populations. Epidemiologic reviews 2009;31:7–20.PubMedCrossRef
52.
Zurück zum Zitat Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, Hamdounia SB, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 2014;59:1411–1419.PubMedCrossRef Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, Patel A, Hamdounia SB, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 2014;59:1411–1419.PubMedCrossRef
53.
Zurück zum Zitat Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transplant international 2005;18:461–466.PubMedCrossRef Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transplant international 2005;18:461–466.PubMedCrossRef
54.
Zurück zum Zitat Seo S, Maganti K, Khehra M, Ramsamooj R, Tsodikov A, Bowlus C, McVicar J, et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transplantation 2007;13:844–847.PubMedCrossRef Seo S, Maganti K, Khehra M, Ramsamooj R, Tsodikov A, Bowlus C, McVicar J, et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transplantation 2007;13:844–847.PubMedCrossRef
Metadaten
Titel
Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals
verfasst von
Albert Do, M.D., M.P.H
Denise A. Esserman, Ph.D.
Supriya Krishnan, Sc.D.
Joseph K. Lim, M.D.
Tamar H. Taddei, M.D.
Ronald G. Hauser III, M.D.
Janet P. Tate, M.P.H., Sc.D.
Vincent Lo Re III, M.D.
Amy C. Justice, M.D., Ph.D.
Publikationsdatum
27.04.2020
Verlag
Springer International Publishing
Erschienen in
Journal of General Internal Medicine / Ausgabe 7/2020
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-05782-6

Weitere Artikel der Ausgabe 7/2020

Journal of General Internal Medicine 7/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.